Metabolic medicine

What the Wegovy Pill and Foundayo Launches Reveal About Access

Compare Wegovy pill and Foundayo prescriptions, Q3 sales and dosing routines. See what research teams can measure to assess access and treatment persistence.

By Lampgen Clinical Research

Two generic silver blister packs on a dark blue surface under the headline The Oral GLP-1 Launch Race.
Editorial illustration of oral medication packaging for Lampgen Clinical Insights.

3 min read · estimated

Sources
~184,000 Wegovy pill~65,000 Foundayo
Tracked U.S. weekly prescriptions in Fierce Pharma’s November 6, 2026 update, based on IQVIA data cited by Jefferies

What the source reported

Novo Nordisk’s Wegovy pill led tracked U.S. prescriptions for oral obesity drugs in the latest Fierce Pharma update, while Eli Lilly’s Foundayo recorded its strongest tracked week so far. Both launches show demand for an oral option. The next question is how many patients can start and stay on treatment once they encounter the realities of coverage, dose escalation and daily use.

Fierce reported approximately 184,000 weekly prescriptions for the Wegovy pill and 65,000 for Foundayo, using IQVIA data cited by Jefferies. Wegovy had an earlier U.S. launch, in January, and Foundayo began shipping in April. Comparing each product at week 30 of its own rollout, the corresponding totals were roughly 173,000 for Wegovy and 65,000 for Foundayo. Matching launch age helps put the gap in context. Coverage, distribution and market conditions still differed across the two launch periods.

For Q3 2026, Novo Nordisk reported global Wegovy pill sales of DKK 5.394 billion, about US$800 million. Lilly reported US$184 million in global Foundayo revenue. Those are quarterly financial figures across launch markets. The weekly prescription figures describe tracked U.S. activity. They include repeat prescriptions, and Novo told analysts that some of its partner channels are underrepresented in IQVIA. Assessing comparative effectiveness or how long people stay on treatment requires additional evidence.

The U.S. labels describe different daily routines. Oral semaglutide (Wegovy) is taken in the morning on an empty stomach with up to four ounces of water, followed by a wait of at least 30 minutes before food, other beverages or oral medicines. Orforglipron (Foundayo) can be taken once daily with or without food. That difference gives researchers a practical question to test. Does dosing flexibility help more people stay on therapy under everyday conditions?

What this means for trial teams

Track where patients lose access. Measure how many new prescriptions are filled, how long the first fill takes and what patients pay. CMS’s Medicare GLP-1 Bridge includes both products for eligible Part D beneficiaries prescribed them for weight management, with a $50 monthly copay. Prior authorization and eligibility rules apply. For an access analysis, distinguish Bridge coverage, other insurance and self-pay. Include pharmacies and dispensing channels where the data can support a reliable comparison.

Follow patients through dose escalation and refills. Define 90- and 180-day persistence using a consistent refill-gap rule. Record treatment switches, dose changes and reasons for stopping, including tolerability, coverage changes and cost. A refill is evidence of dispensing. Patient follow-up can help establish whether people are taking the medicine as intended and how they manage its requirements. A 2025 JAMA Network Open study found frequent discontinuation with earlier GLP-1 therapies in routine care. The two new pills need their own follow-up.

Find out who gains an option. Separate first-time GLP-1 users from people switching therapies and examine results by coverage, geography and patient demographics where data completeness and privacy protections permit. Include community practices in prospective research and ask participants about work schedules, other medicines and pharmacy access. That helps teams assess whether oral treatment reaches people who previously faced barriers to care and whether any gains last beyond the first fill.

Sources

  1. Fierce Pharma, Oral GLP-1 Tracker, November 6, 2026 update
  2. Novo Nordisk, January 2026 U.S. Wegovy pill launch
  3. Lilly, Foundayo U.S. approval and April shipping announcement
  4. Novo Nordisk, Q3 2026 financial report filed with the SEC
  5. Eli Lilly, Q3 2026 financial results
  6. DailyMed, Wegovy U.S. prescribing information
  7. DailyMed, Foundayo U.S. prescribing information
  8. CMS, Medicare GLP-1 Bridge information for Part D plans
  9. Rodriguez et al., GLP-1 discontinuation and reinitiation, JAMA Network Open, 2025
  10. Lampgen Clinical Insights, clinical trial participation burden and patient access

AVAILABLE FOR NEW PARTNERSHIPS

What does your clinical team need next?